Objective: To investigate the effect of fasudil and nimodipine in the clinical treatment of cerebral vasospasm after cerebral aneurysm embolization. Methods: A total of 58 patients with cerebral vasospasm who underwent cerebral aneurysm embolization received from our hospital from April 2018 to April 2019 were enrolled in the study. The random double-blind method was used as a reference group. Example), control group (29 cases); control group treated with nimodipine, observation group treated with nimodipine + fasudil, compared with the two groups of patients before and after treatment (GCS) score, quality of daily life ( Barthel index, neurological deficit (NFI) score, and mean middle cerebral artery flow velocity (MCA). Results: The pre-treatment observations of the two groups were basically the same, that is, the statistical significance of the difference between the corresponding data groups was not established (P>0.05). After treatment, the GCS score and Barthel index of the observation group were higher than the control group, and the NFI score was lower than that of the control group. In the control group, MCA was higher than the control group, that is, there was a statistically significant difference between the groups (P<0.05). Conclusion: The combination of fasudil and nimodipine in the clinical treatment of cerebral vasospasm after cerebral aneurysm embolization is effective, which can improve the clinical symptoms and neurological function of patients, and has a positive effect on the rehabilitation of patients. |